ArticleFrontiers in oncology2026
Case Report: A case of type II cryoglobulinemia secondary to diffuse large B-cell lymphoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse Large B-Cell Lymphoma (DLBCL) represents the most prevalent subtype of Non-Hodgkin Lymphoma (NHL). Cryoglobulinemia results from reversible precipitation of serum immunoglobulin complexes at low temperatures, with Type II (mixed) cryoglobulinemia commonly associated with hepatitis C virus (HCV) infection, autoimmune diseases, and B-cell lymphoproliferative disorders. However, its occurrence secondary to DLBCL is exceedingly rare. This report presents a rare case of DLBCL complicated by Type II cryoglobulinemia, acute liver injury, acute kidney injury, and severe infection. Case report: A female patient in her 40s presented to an external hospital with unexplained high fever, dry cough, and chest tightness. She was diagnosed with DLBCL based on bone marrow cytology and histopathological findings. The patient received chemotherapy with the zuberitamab plus CHOP regimen. However, anaphylactic shock occurred during zuberitamab infusion, leading to temporary discontinuation of chemotherapy. Upon transfer to our hospital, laboratory tests indicated renal insufficiency and severe hepatic injury. Combined with clinical manifestations such as extensive skin and mucosal ecchymoses, bilateral lower limb edema, arthralgia, reversible serum cryoprecipitation, positive mixed type II cryoglobulin, and decreased C4 complement levels, a diagnosis of type II cryoglobulinemia was confirmed. Following fluid resuscitation, diuresis, and continuous renal replacement therapy, her condition temporarily improved. Unfortunately, the patient succumbed due to disease progression of lymphoma. Conclusion: This case illustrates the diagnostic and therapeutic management of type II cryoglobulinemia secondary to DLBCL. It highlights the importance of closely monitoring clinical manifestations and implementing early intervention for related complications during the treatment of B-cell lymphoproliferative disorders, aiming to reduce the high mortality rate and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.